Here's how they compare: For a detailed head-to-head comparison, see our retatrutide vs tirzepatide guide
Detecting disease before it progresses may allow intervention to have the greatest effect (Rosner 2006)
They can provide personalised guidance on how to adjust your injection schedule whilst maintaining therapeutic consistency
Monthly virtual check-ins through Klinic ensure that your treatment plan meets your needs, helping manage side effects and optimizing your nutritional intake
This clinical success has translated into major commercial growth
Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain